4-Hydroperoxyifosfamide
Based on 1 Customer Validation
4-Hydroperoxyifosfamide (4OOH-IFA) is an anticancer agent and a pre-activated derivative of Ifosfamide (HY-17419). 4-Hydroperoxyifosfamide inhibits nucleic acid metabolism and IL-2-stimulated lymphocyte proliferation, depletes GSH, targets HSP27 and caspases-8/9/3/7, and induces apoptosis, necrosis, membrane damage, phosphatidylserine externalization, and loss of mitochondrial potential. 4-Hydroperoxyifosfamide reduces cell viability, inhibits sodium-dependent phosphate transport, and downregulates NaPi-IIa protein and mRNA expression in OK cells. 4-Hydroperoxyifosfamide inhibits the growth of A2780, A2780CP2, MCF-7, and MB231 cells. 4-Hydroperoxyifosfamide is cytotoxic to ovarian/breast cancer cells and has antitumor effects in leukemia L1210 mice. 4-Hydroperoxyifosfamide can be used in research related to cancers such as leukemia.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 98.0%
- CAS. Nr.: 39800-28-7
- Formel: C7H15Cl2N2O4P
- Molecular Weight:293.08
-
Speicherung:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Alle Caspase Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
IC50 & Target
[6]|
Caspase-8 |
Caspase-9 |
Caspase-3 |
Caspase-7 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A2780 | IC50 |
5.5 μM
|
Cytotoxicity against human ovarian A2780 cells assessed as growth inhibition after 2 hrs exposure by SRB assay.
Cytotoxicity against human ovarian A2780 cells assessed as growth inhibition after 2 hrs exposure by SRB assay.
|
000054961 |
| MCF7 | IC50 |
148.6 μM
|
Cytotoxicity against human breast MCF-7 cells assessed as growth inhibition after 2 hrs exposure by SRB assay.
Cytotoxicity against human breast MCF-7 cells assessed as growth inhibition after 2 hrs exposure by SRB assay.
|
000054961 |
| MDA-MB-231 | IC50 |
151.2 μM
|
Cytotoxicity against human breast MB231 cells assessed as growth inhibition after 2 hrs exposure by SRB assay.
Cytotoxicity against human breast MB231 cells assessed as growth inhibition after 2 hrs exposure by SRB assay.
|
000054961 |
In Vitro
4-Hydroperoxyifosfamide (0.5-2.5 μg/mL (MOLT-4); 1-10 μg/mL (mL-1); 24-48 h) dissipates the mitochondrial membrane potential in MOLT-4 and mL-1 leukemia cells[6].
4-Hydroperoxyifosfamide inhibits IL-2-stimulated human PBL proliferation in a dose-dependent manner and does not reduce viability at 100 μM[2].
4-Hydroperoxyifosfamide induces HSP27 phosphorylation in human PBL and converts almost all HSP27A to the phosphorylated isoform[2].
4-Hydroperoxyifosfamide (4-OH-Ifo) (50-100 μM; 24 h) reduces viability in OK cells in a concentration-dependent manner[3].
4-Hydroperoxyifosfamide (10-100 μM; 24 h) inhibits sodium-dependent phosphate transport in OK cells, and this inhibition is not prevented by MESNA[3].
4-Hydroperoxyifosfamide decreases NaPi-IIa protein abundance in OK cells in a dose-dependent manner without altering NHE3 or Na-K-ATPase[3].
4-Hydroperoxyifosfamide (50 μM; 24 h) reduces NaPi-IIa mRNA expression[3].
4-Hydroperoxyifosfamide (4-OOH-IF) (2 h) inhibits the growth of A2780, A2780CP2, MCF-7, and MB231 cells, with IC50 values of 5.5-151.2 μM[4].
4-Hydroperoxyifosfamide (5.5-151.2 μM; 2-24 h) maximally depletes cellular glutathione in MCF-7 and MB231 at 2 hours and restores levels at 24 hours; it does not significantly alter glutathione peroxidase activity in A2780, A2780CP2, MCF-7, or MB231 cells[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:opossum kidney (OK) cells (clone 3B2, passages 10-35)
-
Concentration:0, 1, 5, 10, 50, 100, 250, 500, 1000 μM
-
Incubation Time:24 h
-
Result:Decreased cell survival in a concentration-dependent manner.
-
Cell Line:human acute lymphoblastic leukemia MOLT-4 and human acute myeloblastic leukemia mL-1 cells
-
Concentration:0.5, 1, 2.5 μg/mL (MOLT-4); 1, 5, 10 μg/mL (mL-1)
-
Incubation Time:24 h and 48 h
-
Result:Reduced the FDA+/PI− live-cell population and increased FDA−/PI− and FDA−/PI+ populations in MOLT-4 and mL-1 cells; effects were dose- and time-dependent and weaker in mL-1 cells than in MOLT-4 cells.
-
Cell Line:human acute lymphoblastic leukemia MOLT-4 and human acute myeloblastic leukemia mL-1 cells
-
Concentration:0.5, 1, 2.5 μg/mL (MOLT-4); 1, 5, 10 μg/mL (mL-1)
-
Incubation Time:24 h and 48 h
-
Result:Induced apoptotic and necrotic cell death, with increased annexin V-FITC+/PI− and annexin V-FITC+/PI+ cell populations; the effect was weaker in mL-1 cells than in MOLT-4 cells.\nPromoted caspase-8, caspase-9, and caspase-3/7 activation in MOLT-4 and mL-1 cells; activation was weaker in mL-1 cells.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL × DBA/2 (were administered i.p. on the 1st day of inoculation of 105 or 106 leukemia cells)
[5] -
Dosage:100 mg/kg (105-cell inoculum); 154 mg/kg (106-cell inoculum)
-
Administration:i.p.; on the 1st day of inoculation
-
Result:Achieved 100% 30‑day survivors with 4‑Hydroperoxyifosfamide at 100 mg/kg at the 105‑cell inoculum.
Achieved 100% 30‑day survivors with 4‑Hydroperoxyifosfamide at 154 mg/kg at the 106‑cell inoculum.
- RT-PCR
- RNA extraction experimental
- Mammalian live/dead viability and cytotoxicity staining
- Annexin V plus membrane-impermeant dye apoptosis staining
- CFSE Dye Dilution Proliferation Assay
- CCK-8/WST-8 Cell Proliferation Assay
- Breast Cancer Modeling
- Real Time qPCR (Q-PCR)
- Cell Viability Determination by MTT Colorimetric Assay
- Detection of Apoptosis
- TUNEL staining for apoptotic DNA fragmentation
- Cell Cytotoxicity Assay
- Apoptosis Solutions
- MTT Cell Proliferation Assay
Chemical Information
-
CAS. Nr. 39800-28-7
-
Appearance Solid
-
Molecular Weight 293.08
-
Formel C7H15Cl2N2O4P
-
Color White to off-white
-
SMILES
OOC1N(CCCl)P(OCC1)(NCCCl)=O
-
Synonyms
4OOH-IFA
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : ≥ 100 mg/mL (341.20 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 5 mg/mL (17.06 mM; ultrasonic and warming and heat to 60°C)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.53 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.53 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (295 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
Verweise
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 3.4120 mL | 17.0602 mL | 34.1204 mL | 85.3009 mL |
| 5 mM | 0.6824 mL | 3.4120 mL | 6.8241 mL | 17.0602 mL | |
| 10 mM | 0.3412 mL | 1.7060 mL | 3.4120 mL | 8.5301 mL | |
| 15 mM | 0.2275 mL | 1.1373 mL | 2.2747 mL | 5.6867 mL | |
| DMSO | 20 mM | 0.1706 mL | 0.8530 mL | 1.7060 mL | 4.2650 mL |
| 25 mM | 0.1365 mL | 0.6824 mL | 1.3648 mL | 3.4120 mL | |
| 30 mM | 0.1137 mL | 0.5687 mL | 1.1373 mL | 2.8434 mL | |
| 40 mM | 0.0853 mL | 0.4265 mL | 0.8530 mL | 2.1325 mL | |
| 50 mM | 0.0682 mL | 0.3412 mL | 0.6824 mL | 1.7060 mL | |
| 60 mM | 0.0569 mL | 0.2843 mL | 0.5687 mL | 1.4217 mL | |
| 80 mM | 0.0427 mL | 0.2133 mL | 0.4265 mL | 1.0663 mL | |
| 100 mM | 0.0341 mL | 0.1706 mL | 0.3412 mL | 0.8530 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.